Bortezomib S.K is indicated for the treatment of patients with multiple myeloma.
Mantle Cell Lymphoma Bortezomib S.K is indicated for the treatment of patients with mantle cell Lymphoma who have received at least one prior therapy.
Bortezomib S.K in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
